Ad

MDP – Medexus Pharmaceuticals Inc

Compliant

★★☆☆☆

Medexus Pharmaceuticals Inc is Shariah compliant. The company’s financials pass two standards and fail in three.

$40,183,541

Market cap

69.68%

Revenue Growth

BUY

Analysts' Rating

Ad

Recommendation Rating

2.5

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 5.11

Low: 2.36

High: 11.21

Total Analysts: 3

Company Profile

Medexus Pharmaceuticals Inc. is a Canada-based rare disease pharmaceutical company. The Company is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The Company is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The Company’s products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. It also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses